Search
Agalsidase beta
go.drugbank.com/drugs/DB00103ApprovedInvestigational[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … [A220343] Agalsidase beta was granted FDA approval on 24 April 2003.[L16383]
Succinylcholine
go.drugbank.com/drugs/DB00202ApprovedInvestigational[A19054] It has been widely used for over 50 years,[A299] most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. … Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short
Synonyms: 2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)Products: Suxamethonium Aguettant 10 mg/ml Injektionslösung in einer FertigspritzeClobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigational[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974. … [A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]
Synonyms: Clobetasol propionate EInternational brands: Embeline EFactor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalFactor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation … Also known as Fibrin Stabilizing Factor (FSF), Factor XIII is an endogenously produced coagulation factor and the final enzyme within the blood coagulation cascade.
Minocycline
go.drugbank.com/drugs/DB01017ApprovedInvestigationalMinocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. … [A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695]
Umeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigationalANORO ELLIPTA was approved in December 2013 while TRELEGY ELLIPTA was approved in September 2017.[L46881,L46886] … [A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product.
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigational[A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323] … Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease.
Oleic Acid
go.drugbank.com/drugs/DB04224ApprovedInvestigationalVet approved(Stedman, 26th ed) … An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent.
Mixtures: Huile D'onagre Vitamin EAncestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawnIt is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal … [T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087]